| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| James R Barnett, Reid A Grinspoon, Mukesh Harisinghani, Paul A Caruso, Elizabeth A Thiel. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 77. 2020-11-05. PMID:32409220. |
in patients with tuberous sclerosis complex (tsc) the upregulation of the mechanistic target of rapamycin (mtor) pathway leads to the development and growth of subependymal giant cell tumors (sgcts) and renal angiomyolipomas (amls). |
2020-11-05 |
2023-08-13 |
Not clear |
| Till S Zimmer, Diede W M Broekaart, Victoria-Elisabeth Gruber, Erwin A van Vliet, Angelika Mühlebner, Eleonora Aronic. Tuberous Sclerosis Complex as Disease Model for Investigating mTOR-Related Gliopathy During Epileptogenesis. Frontiers in neurology. vol 11. 2020-10-13. PMID:33041976. |
tuberous sclerosis complex (tsc) represents the prototypic monogenic disorder of the mammalian target of rapamycin (mtor) pathway dysregulation. |
2020-10-13 |
2023-08-13 |
Not clear |
| Fang Fang, Xiaoxi Wei, Min Hu, Fei Li. A mouse model of craniofacial bone lesion of tuberous sclerosis complex. Musculoskeletal regeneration. vol 1. issue 1. 2020-10-01. PMID:26052552. |
the best known and characterized mtor signaling dysregulation in human disease is called tuberous sclerosis complex (tsc). |
2020-10-01 |
2023-08-13 |
mouse |
| Suna Emir, Şadan Hacısalihoğlu, Derya Özyörük, Filiz Ekici, Aydan Değerliyurt, Alev Güven, İlker Çeti. Assessment of tumors in children with tuberous sclerosis: a single centre's experience. Turk pediatri arsivi. vol 52. issue 1. 2020-10-01. PMID:28439198. |
as a result of mutations in tsc1 (9q34) and tsc2 (16p13.3) tumor supressor genes, the mammalian target of the rapamycin (mtor) signaling pathway is overactivated in patients with tuberous sclerosis. |
2020-10-01 |
2023-08-13 |
Not clear |
| Susana Boronat, Ignasi Barber, Elizabeth Anne Thiel. Sclerotic bone lesions in tuberous sclerosis complex: A genotype-phenotype study. American journal of medical genetics. Part A. vol 173. issue 7. 2020-10-01. PMID:28488386. |
tuberous sclerosis complex (tsc) is due to pathogenic variants in tsc1 or tsc2 genes resulting in hyperactivation of the mtor pathway. |
2020-10-01 |
2023-08-13 |
Not clear |
| Zixuan Zhang, Mengzhao Wan. PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours. Oncology letters. vol 14. issue 2. 2020-10-01. PMID:28789352. |
in total, 4 missense mutations were found in 3 patients with tc/ac, including mutations in exon 48 of mtor (c.6667c>t), exon 21 of tuberous sclerosis complex (tsc) 1 (c.2765g>a), and exons 12 (c.1265c>t) and 19 (c.2148c>t) of tsc2. |
2020-10-01 |
2023-08-13 |
Not clear |
| Michael Yoon Kang, Joey Yeoh, Ashwini Pondicherry, Habib Rahman, Ajith Dissanayak. Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality? Journal of the Endocrine Society. vol 1. issue 9. 2020-10-01. PMID:29264566. |
insulinoma and tuberous sclerosis: a possible mechanistic target of rapamycin (mtor) pathway abnormality? |
2020-10-01 |
2023-08-13 |
Not clear |
| Kunio Yui, George Imataka, Hitomi Sasaki, Yohei Kawasaki, Tohru Okanshi, Ryoichi Shiroki, Shigemi Yoshihar. Improvement in Impaired Social Cognition but Not Seizures by Everolimus in a Child with Tuberous Sclerosis-Associated Autism through Increased Serum Antioxidant Proteins and Oxidant/Antioxidant Status. Case reports in pediatrics. vol 2019. 2020-10-01. PMID:31871809. |
we investigated the effect of the mammalian target of rapamycin (mtor) inhibitor everolimus on tuberous sclerosis complex- (tsc-) associated autistic symptoms and focal seizures with impaired awareness in a female child with tsc. |
2020-10-01 |
2023-08-13 |
Not clear |
| Jinhyun Cho, Jeeyun Lee, Jusun Kim, Seung Tae Kim, Sujin Lee, Sun Young Kim, Sang Yun Ha, Cheol-Keun Park, Ho Yeong Li. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. Translational oncology. vol 9. issue 5. 2020-09-30. PMID:27751352. |
loss of tuberous sclerosis complex 2 (tsc2) as a predictive biomarker of response to mtor inhibitor treatment in patients with hepatocellular carcinoma. |
2020-09-30 |
2023-08-13 |
Not clear |
| Jinhyun Cho, Jeeyun Lee, Jusun Kim, Seung Tae Kim, Sujin Lee, Sun Young Kim, Sang Yun Ha, Cheol-Keun Park, Ho Yeong Li. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. Translational oncology. vol 9. issue 5. 2020-09-30. PMID:27751352. |
tumors with loss of tuberous sclerosis complex 2 (tsc2), a negative regulator of mtor signaling, tend to respond well to mtor inhibitors. |
2020-09-30 |
2023-08-13 |
Not clear |
| Wobke E M van Dijk, Menno A M H Vergeer, Joop E Arend. Persistent Hepatitis E Infection in a Patient with Tuberous Sclerosis Complex Treated with Everolimus: A Case Report. Infectious diseases and therapy. vol 6. issue 2. 2020-09-30. PMID:28258506. |
we present the first case of hev infection in a patient with tuberous sclerosis complex (tsc) treated with everolimus, a mammalian target of rapamycin (mtor) inhibitor. |
2020-09-30 |
2023-08-13 |
Not clear |
| Shuang Ji, Wei Lin, Li Wang, Zhaofei Ni, Fuquan Jin, Xiaojun Zha, Guanghe Fe. Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex. Journal of Cancer. vol 8. issue 4. 2020-09-30. PMID:28367235. |
combined targeting of mtor and akt using rapamycin and mk-2206 in the treatment of tuberous sclerosis complex. |
2020-09-30 |
2023-08-13 |
Not clear |
| Rinzhin T Sherpa, Kimberly F Atkinson, Viviana P Ferreira, Surya M Naul. RAPAMYCIN INCREASES LENGTH AND MECHANOSENSORY FUNCTION OF PRIMARY CILIA IN RENAL EPITHELIAL AND VASCULAR ENDOTHELIAL CELLS. International education and research journal. vol 2. issue 12. 2020-09-30. PMID:28529994. |
rapamycin, a potent inhibitor of mtor (mammalian target of rapamycin), has been demonstrated to be a potential pharmacological agent against the aberrant mtor signaling seen in ciliopathies such as polycystic kidney disease (pkd) and tuberous sclerosis complex (tsc). |
2020-09-30 |
2023-08-13 |
mouse |
| Zuowei Hu, Xiaoye Zhang, Hang Yang, Shuanglai Qin, Yaqi Liu, Wei Xiong, Bing Yuan, Liping Li, Weiqi Yao, Dongcheng W. Alterations in expression levels of genes in p53-related pathways determined using RNA-Seq analysis in patients with breast cancer following CIK therapy. Oncology letters. vol 14. issue 6. 2020-09-30. PMID:29344236. |
the expression levels of 8 genes were analyzed, including tumor suppressor protein 53 (tp53), murine double minute homolog 2 (mdm2), ribosomal protein l11 (rpl11), ribosomal protein s23 (rps23), sirtuin 1, histone deacetylase 1, tuberous sclerosis complex 1 (tsc1) and mechanistic target of rapamycin (mtor), and alterations in expression levels following cik therapy were determined. |
2020-09-30 |
2023-08-13 |
Not clear |
| Jennifer L Griffith, Michael Won. The mTOR pathway in treatment of epilepsy: a clinical update. Future neurology. vol 13. issue 2. 2020-09-30. PMID:30505235. |
hyperactivation of the mtor pathway has been implicated in tuberous sclerosis complex and other 'mtoropathies', clinical syndromes associated with cortical developmental malformations and drug-resistant epilepsy. |
2020-09-30 |
2023-08-13 |
Not clear |
| Jennifer L Griffith, Michael Won. The mTOR pathway in treatment of epilepsy: a clinical update. Future neurology. vol 13. issue 2. 2020-09-30. PMID:30505235. |
recently published clinical trials of mtor inhibitors in tuberous sclerosis complex have shown that these drugs are effective at decreasing seizure frequency. |
2020-09-30 |
2023-08-13 |
Not clear |
| Alice Crane, Mohamed Eltemamy, Daniel Shoske. Transplant immunosuppressive drugs in urology. Translational andrology and urology. vol 8. issue 2. 2020-09-30. PMID:31080770. |
also included is the utilization of mtor inhibitors in both advanced renal cell carcinoma (rcc) and in patients with tuberous sclerosis complex (tsc) associated angiomyolipoma (aml). |
2020-09-30 |
2023-08-13 |
Not clear |
| Hyea Park, Chi Son Chang, Suk-Joo Choi, Soo-Young Oh, Cheong-Rae Ro. Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis. Obstetrics & gynecology science. vol 62. issue 4. 2020-09-30. PMID:31338346. |
the mtor inhibitors are well-known to have anti-tumor activity, and they have been used for the treatment of patients with tuberous sclerosis. |
2020-09-30 |
2023-08-13 |
Not clear |
| Guang Yang, Lu Yang, Xiaofan Yang, Xiuyu Shi, Jing Wang, Yujie Liu, Jun Ju, Liping Zo. Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis. Experimental and therapeutic medicine. vol 9. issue 2. 2020-09-29. PMID:25574245. |
inhibitors of mammalian target of rapamycin (mtor) are increasingly used as therapy for pediatric patients with tuberous sclerosis complex (tsc). |
2020-09-29 |
2023-08-13 |
Not clear |
| Yu Xing, Yan-Xia Liu, Xin Liu, Shu-Lin Wang, Ping Li, Xiao-Hua Lin, Cong-Lu Sui, Cai Xu, Bing Qi, Qing Ton. Effects of Gui Zhu Yi Kun formula on the P53/AMPK pathway of autophagy in granulosa cells of rats with polycystic ovary syndrome. Experimental and therapeutic medicine. vol 13. issue 6. 2020-09-29. PMID:28588681. |
expression levels of beclin-1, light chain (lc)3, mechanistic target of rapamycin (mtor), tumor suppressor p53 (p53), adenosine monophosphate-activated protein kinase (ampk), sestrin2 and tuberous sclerosis protein 1/2 were evaluated using quantitative polymerase chain reaction and western blotting. |
2020-09-29 |
2023-08-13 |
rat |